You are now leaving the Viatris page for a Viatris affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Viatris affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.
Unified by their commitment to helping patients address their evolving healthcare needs, our industry-leading team of executives and board members will guide Viatris into the future of global healthcare.
Robert J. Coury
After leading the transformation of Mylan into one of the world's largest global pharmaceutical companies, Robert J. Coury again led the company to another level by combining forces with Upjohn to form Viatris, a new champion for global health. His strategic vision and leadership guide the company's performance and growth.
Viatris chief executive officer Scott A. Smith is a deeply knowledgeable senior global biotechnology and
pharmaceutical executive with more than 35 years of experience. He is a seasoned builder who
possesses vast global commercial and pharmaceutical expertise and a proven ability to build, grow and
manage large complex organizations. Before becoming Viatris’ CEO, Smith was President and Chief
Operating Officer of Celgene Corp. Most recently, he served as President of BioAtla, Inc., a global
biotechnology company focused on the development of Conditionally Active BiologicsTM (CAB) antibody
therapeutics. Smith is a member of Viatris board of directors.
Rajiv Malik began his pharmaceuticals career as a scientist and went on to become a leading pharmaceutical industry executive with more than 60 process patents to his name. His deep commercial, scientific and operational experience is an invaluable asset in his role as president of Viatris.
Sanjeev Narula was appointed as the chief financial officer of Viatris following 16 years of experience in senior financial leadership positions at Pfizer. He has a deep understanding of financial and commercial dynamics across geographies and in all Viatris markets.